CurrentAnthemPolicy 09-600

Therapeutic Parenteral Drug Administration

Defines dental coverage review criteria for therapeutic parenteral administration of medications (IV/IM/SC/ID) in dental care and what documentation/coding is expected; applies to providers and claims adjudication under the dental plan.

Policy Summary

PayerAnthem

PolicyTherapeutic Parenteral Drug Administration

Policy CodePolicy 09-600

Change TypeNo material changes

Effective Date01/01/2024

Key ActionSubmit clinical rationale plus medication name and dosage for prior review and benefit determination.

Next Review DateN/A

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3CDT codes listed

4Required documentation items

2024-01-01Policy publish date

Coverage Criteria

Covered when ALL of the following are met

Therapeutic parenteral drug administration is considered for benefit determination when the service meets generally accepted standards of dental practice and documentation requirements.

Standards of care: Service is in accordance with generally accepted standards of dental practice (based on peer-reviewed evidence, specialty society recommendations, and recognized practicing dentists).

Purpose: Administration is for therapeutic indications such as improving surgical healing, reducing pain, or treating infection (includes antibiotics, steroids, anti-inflammatory drugs or other therapeutic medications).

Route: Administration route must be parenteral (intravenous, intramuscular, subcutaneous, or intradermal).

Documentation:

Policy Summary

PayerAnthem

PolicyTherapeutic Parenteral Drug Administration

Policy CodePolicy 09-600

Change TypeNo material changes

Effective Date01/01/2024

Key ActionSubmit clinical rationale plus medication name and dosage for prior review and benefit determination.

Next Review DateN/A

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Services that are primarily cosmetic in nature, or procedures that are considered experimental, investigational or unproven, are not benefitted and therefore are not considered medically/dentally necessary under this policy. Additionally, any service that does not meet generally accepted standards of dental practice (based on peer‑reviewed evidence, specialty society recommendations, and recognized practicing dentists) will not be considered covered. Providers should expect that such services may be denied when submitted for benefit determination.

Provider Actions & Requirements

Prior Authorization

Prior review / benefit determination

Providers must submit clinical rationale and request prior review/benefit determination when therapeutic parenteral drug administration is billed. Benefit determination requires documentation showing the service meets generally accepted standards of dental care and is appropriate for the patient’s condition.

Prior review/benefit determination may be required before payment will be approved.

Documentation Required

Required documentation

Submit clinical chart notes, medication name, dosage, and rationale with the claim or upon request. Include documentation that the drug is therapeutic (antibiotic, steroid, anti-inflammatory or other therapeutic medication) and not a sedative, anesthetic, reversal agent, cosmetic agent, or sustained‑release long‑acting pain control implant.

Clinical chart notes and narrative may be requested to explain the rationale for the medication.
The name and dosage of the medication administered must be submitted for benefit consideration.

Billing Rule

Provider action / billing highlight

Actionable billing highlight: ensure coding reflects parenteral routes (IV, IM, SC, ID) and that the service is reported only for therapeutic drug administration—not for sedation/anesthesia or cosmetic indications. Do not report infiltration of sustained‑release pharmacologic agents for long‑acting surgical site pain control as therapeutic parenteral drug administration.

Parenteral routes: intravenous, intramuscular, subcutaneous, intradermal.
Do not use these codes for sedative, anesthetic, or reversal agents.
Cosmetic drug administration is not a benefitted service.

Denial Risk

Denial triggers

Claims may be denied if documentation does not support that the service meets generally accepted standards of dental practice, is medically necessary, is not primarily cosmetic, or if the procedure is experimental, investigational, or unproven. Denials may also occur when a more cost‑effective alternative is available or when required clinical information (chart notes, medication name/dose, rationale) is not provided.

Denial triggers: not meeting accepted standards of dental practice; cosmetic indication; experimental/investigational/unproven procedures; missing required documentation; more cost‑effective alternative exists.

Background

Therapeutic parenteral drug administration in dental practice refers to administration by intravenous (IV), intramuscular (IM), subcutaneous (SC), or intradermal (ID) routes. It includes single or multiple administrations of antibiotics, steroids, anti‑inflammatory agents or other therapeutic medications intended to improve surgical healing, reduce pain, or treat infection. Providers must submit clinical chart notes and narrative explaining the rationale for the medication, and the name and dosage of the medication administered, to allow benefits review and determination under the member's contract.

D9610	Therapeutic parenteral drug, single administration
D9612	Therapeutic parenteral drugs, two or more administrations, different medications
D9613	Infiltration of sustained release therapeutic drug - single or multiple sites

OpenPayer

Therapeutic Parenteral Drug Administration

Coverage Criteria

Coding

Provider Actions & Requirements

Background

Definitions